The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo

Cancer Gene Therapy

Volumn 4, Issue 4, 1997, Pages 213-221

  Elshami, Ashraf A ^a   Cook, Judith Wood ^a   Amin, Kunjlata M ^a   Choi, Hester ^a   Park, Jae Y ^a   Coonrod, Laura ^a   Sun, Jing ^a   Molnar Kimber, Katherine ^a   Wilson, James M ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenovirus; Cancer; Ganciclovir; Gene therapy; HSV thymidine kinase

Indexed keywords

THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; EXPERIMENTAL NEOPLASM; FISCHER 344 RAT; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; PROMOTER REGION; RAT;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); RATS; RATS, INBRED F344; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0031183492     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cane Gene Ther. 1994;1:279-287.
2. Moolten FL, Wells M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Canc Inst. 1990;82:297-300.
3. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev of Infect Dis. 1988;10:S490-S494.
4. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther. 1995;2:50-58.
5. Li Bi W, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Human Gene Ther. 1993;4:725-731.
6. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
7. Freeman SM, Abboud CN, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
8. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 1994;54:2055-2059.
9. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Resp Cell Mol Biol. 1995;13:7-16.
10. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
11. O'Malley BW, Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995;55:1080-1085.
12. Perez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Woo SL, Grossman RG, Shine HD. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res. 1994;39: 506-511.
13. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83-88.
14. Izquierdo M, Martín V, de Felipe P, et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. 1996; 3:491-495.
15. Treat J, Kaiser LR, Sterman DH, et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.01RSVTK: a phase 1 trial. Human Gene Ther. 1996;7: 2047-2057.
16. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA. 1994;91:10732-10736.
17. Chang MW, Ohno T, Gordon D, et al. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med. 1995;1:172-181.
18. Ezzedine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991;3:608-614.
19. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by type-specific expression of herpes simplex thymidine kinase gene. Cancer Res. 1994;53:5258-5261.
20. Elshami AA, Kucharczuk JC, Zhang HB, et al. Treatment of malignant pleural mesothelioma in an immunocompetent rat model utilizing adenovirus-mediated gene therapy. Human Gene Ther. 1996;7:141-148.
21. Smythe WR, Kaiser LR, Amin KM, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thor Surg. 1994;57: 1395-1401.
22. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniqes. 1988;6: 616-629.
23. Englehardt JF, Simon RH, Yang Y, et al. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: biological efficacy study. Human Gene Ther. 1993;4:759-769.
24. Wagner EF, Stewart TA, Mintz B. The human beta-globin gene and a functional viral thymidine kinase gene in developing mice. Proc Natl Acad Sci USA. 1981;78:5016-5020.
25. Albelda SM, Muller WA, Buck CA, Newman PJ. Molecular and cellular properties of PECAM-1 (endoCAM/ CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol. 1991;114:1059-1068.
26. Craighead JE, Akley NJ, Gould LB, Libbus BG. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Path. 1987;129:448-462.
27. Kucharczuk JC, Elshami A, Zhang H, et al. An intrapleural model of malignant mesothelioma in an immune competent animal to study gene transfer. Ann Thorac Surg. 1995;60:593-598.
28. Culver KW, Ram Z, Wallbridge S., Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
29. Chen C-Y, Chang Y-N, Ryan P, Linscott M, McGarrity GJ, Chiang YL. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediatcd cytotoxicity and the "bystander effect." Human Gene Ther. 1995; 6:1467-1476.
30. Hoganson DK, Batra RK, Olsen JC, Boucher RC. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and the bystander effect in lung adenocarcinoma. Cancer Res. 1996;56:1315-1323.
31. Spadari S, Ciarrocchi G, Focher F, et al. 5-Iodo-2′-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2′-deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies. Mol Phannacol. 1995;47:1231-1238.
32. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem. 1993;268:6332-6337.
33. Black ME, Newcomb TG, Wilson H-MP, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA. 1996;93:3525-3529.